2022 年半年度报告 公司代码：688488 公司简称：艾迪药业 江苏艾迪药业股份有限公司 2022 年半年度报告 1 / 190 2022 年半年度报告 重要提示 一、本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、重大风险提示 1、本期人源蛋白粗品业务销售规模持续缩减 报告期内，天普生化向公司采购人源蛋白粗品约 870 万元，较上年同期减少 86.94%；报告期 内，公司人源蛋白业务实现收入约 4,052.40 万元，较上年同期减少约 69.30%。由于目前人源蛋白 业务为公司主要的收入及利润来源，公司人源蛋白业务收入规模的缩减，会直接导致公司盈利水 平下降。 2、业绩大幅下滑或亏损的风险 本期公司亏损约 6,819.16 万元，若公司出现人源蛋白粗品业务销售规模持续下滑、抗 HIV 新 药无法取得预期的销售规模或市场占有率、在研产品临床进度不及预期或者研发投入持续加大， 或公司无法有效控制运营成本及费用等情况，均可能导致公司亏损状态持续存在或持续扩大。 3、公司新药研发不达预期以及研发投 ...

2022 年第一季度报告 证券代码：688488 证券简称：艾迪药业 江苏艾迪药业股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人傅和亮、主管会计工作负责人俞克及会计机构负责人（会计主管人员）俞克保证季度 报告中财务报表信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | | | 单位：元 | 币种：人民币 | | --- | --- | --- | --- | | 项目 | 本报告期 | | 本报告期比上年 | | | | | 同期增减变动幅 | | | | | 度(%) | | 营业收入 | | 35,101,031.38 | -54.96 | | 归属于上市公司股东的净利润 | | -22,302,749.04 | -296.87 | | 归 ...

Revenue and Profitability - The company reported a significant increase in revenue, with a year-over-year growth of 25% in the latest fiscal year[16]. - The company's operating revenue for 2021 was CNY 255.71 million, a decrease of 11.54% compared to CNY 289.06 million in 2020[26]. - The net profit attributable to shareholders was CNY -29.99 million, a decline of 175.39% from CNY 39.77 million in the previous year[26]. - The basic earnings per share decreased to CNY -0.07, down 170% from CNY 0.10 in 2020[28]. - The cash flow from operating activities showed a net outflow of CNY -12.37 million, a decrease of 122.02% compared to the previous year[26]. - The gross margin improved to 45%, up from 40% in the previous year, reflecting better cost management and pricing strategies[16]. - The company's human protein business revenue decreased by 8.19%, while pharmaceutical business revenue increased by 22.93%[37]. - The human-derived protein business generated revenue of CNY 193.34 million, a decrease of 8.19% year-over-year[128]. - The pharmaceutical business achieved revenue of CNY 31.39 million, an increase of 22.93% year-over-year[129]. Research and Development - The company plans to increase R&D investment in the fields of anti-HIV new drug development and human-derived protein formulations, which may lead to higher R&D expenses and impact current performance[6]. - Investment in R&D has increased by 15%, focusing on the development of innovative biopharmaceuticals and advanced production techniques[19]. - Research and development expenses accounted for 29.97% of operating revenue, an increase of 14.26 percentage points from 15.71% in 2020[28]. - The company has 20 ongoing projects, including 9 Class 1 new drugs and 3 Class 2 new drugs, with its first anti-HIV Class 1 innovative drug, Aibond® (Ainovelin Tablets), approved for sale in June 2021[49]. - The company has developed a unique online adsorption technology for human protein production, significantly improving efficiency and reducing costs compared to traditional methods[78]. - The company has submitted a total of 62 patent applications and obtained 37 authorized patents, including 16 invention patents as of December 31, 2021[87]. - The company's R&D expenditure for the reporting period accounted for 29.97% of its operating income, and 5.85% of its net assets[174]. Market Strategy and Expansion - The company projects a revenue growth of 20% for the next fiscal year, driven by new product launches and market expansion strategies[18]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[16]. - A strategic acquisition of a smaller biotech firm is expected to enhance the company's product pipeline and accelerate growth[17]. - The company aims to cover over 350 drug varieties in each province by the end of 2022, promoting a competitive environment in the pharmaceutical industry[79]. - The company is actively exploring and expanding overseas business opportunities, seeking new growth points in overseas protein sources, and advancing exploratory work for overseas collaborations with Aibond® and ACC008[195]. Customer and Supplier Relationships - The main customer, Tianpu Biochemical, accounted for 54.69% of the company's revenue from human-derived protein products, with a reduction in purchases amounting to approximately 78.2 million yuan during the reporting period[4]. - The company revised its annual procurement framework contract with Tianpu Biochemical, reducing the annual transaction amount from 200 million RMB to 100 million RMB, resulting in a decrease in procurement of approximately 78.2 million RMB during the reporting period[42]. - The gross profit contribution from Tianpu Biochemical exceeded 50% of the company's total, indicating a reliance on this customer for profitability[140]. Product Development and Innovation - The innovative drug Aibond® was approved for market entry on June 25, 2021, and was included in the national medical insurance directory in November 2021[38]. - The company is developing a three-in-one compound formulation ACC008, which has completed bioequivalence testing and is currently under review for market approval[40]. - The company is focused on expanding its pipeline of anti-HIV drugs to meet the urgent treatment needs in China[41]. - The company is developing a new three-in-one combination drug, ACC008, which has completed bioequivalence testing and is currently under review for new drug application[54]. - The company has developed a formulation technology for ACC008 that addresses solubility and stability issues, enhancing bioavailability in human blood[85]. Financial Health and Investment - The company has obtained a bank credit line of 280 million yuan to support its operational funding needs[111]. - The company reported a significant increase in construction in progress to ¥95.23 million, representing 6.64% of total assets, up 453.35% due to new factory expenditures[151]. - The company has invested a total of approximately ¥305.09 million in various research projects, with a current period investment of ¥73.14 million[96]. - The company has signed a technology transfer contract for the anti-tumor project ACC006, receiving a technology transfer fee of 100 million RMB from Guangzhou Lixin Biotechnology Co., Ltd.[44]. Regulatory Environment and Compliance - The company adheres to relevant laws and regulations, continuously improving internal controls to ensure legal and compliant operations[200]. - Recent regulatory reforms, including the establishment of a green channel for new drug approvals, are expected to enhance the speed of domestic innovative drug approvals, stimulating R&D enthusiasm among local companies[82]. - Future medical policies will focus on enhancing drug regulation, improving medical accessibility, and increasing payment efficiency, benefiting high clinical value innovative drugs[83].

2021 年第三季度报告 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期 | | 年初至报告期 | | --- | --- | --- | --- | --- | | | | 比上年同 | 年初至报告期末 | 末比上年同期 | | | | 期增减变 | | 增减变动幅度 | | | | 动幅度(%) | | (%) | | 营业收入 | 52,604,118.51 | -14.04 | 209,607,873.47 | 10.37 | | 归属于上市公司股东的 | -6,220,358.11 | -222.02 | 6,640,689.77 | -77.56 | | 净利润 | | | | | | 归属于上市公司股东的 | | | | | | 扣除非经常性损益的净 | -9,064,178.92 | -1,307.17 | -5,329,073.22 | -126.16 | | 利润 | | | | | 证券代码：688488 证券简称：艾迪药业 江苏艾迪药业股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚 ...

Client Dependence and Risks - The company reported a significant reliance on its major client, Tianpu Biochemical, for human-derived protein sales, which poses a risk to its operational performance if there are fluctuations in Tianpu's business conditions[4] - The company is facing risks related to the commercialization of its innovative drugs, as market acceptance and inclusion in medical insurance directories remain uncertain[5] - The company is committed to addressing various risk factors in its production and operations, as detailed in the management discussion section of the report[6] - The company faces risks related to core talent retention and potential competition in the human-derived protein market[71][74] - The commercialization of Aibond® may face challenges in market acceptance and integration into medical insurance, impacting sales performance[75] Financial Performance - The company's operating revenue for the first half of 2021 was ¥157,003,754.96, representing a 21.97% increase compared to ¥128,719,265.25 in the same period last year[22] - The net profit attributable to shareholders decreased by 47.49% to ¥12,861,047.88 from ¥24,492,586.55 year-on-year[22] - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 80.96% to ¥3,735,105.70 compared to ¥19,619,358.29 in the previous year[22] - The net cash flow from operating activities decreased by 214.25%, resulting in a net outflow of ¥46,647,209.22, primarily due to increased cash expenditures for raw material procurement[22] - The company's gross profit margin for the reporting period was 34.29%, down from 51.86% in the previous year, attributed to a shift in product mix towards lower-margin products[22] Research and Development - The innovative anti-HIV drug Aibond® was successfully approved for market sales during the reporting period, representing a strategic upgrade over existing non-nucleoside reverse transcriptase inhibitors[5] - The pipeline of innovative drugs is at various stages of development, with several still in early clinical trials, indicating potential delays in the new drug development process due to multiple influencing factors[6] - Research and development expenses accounted for 24.2% of operating revenue, an increase of 11.9 percentage points from 12.3% in the previous year[23] - The company has 16 products in the research pipeline, including 8 Class 1 new drugs and 3 Class 2 new drugs[29] - The company is actively developing downstream formulations in the human-derived protein sector, including clinical research for new indications of Ustectidine and new formulations of Urekin[4] Drug Development and Market Strategy - The first Class 1 innovative drug, Aibond® (Ainovelin Tablets), was approved for sale in June 2021, targeting HIV-1 infection in treatment-naive patients[29] - Aibond® has a half-life of approximately 26 hours, requiring only one dose per day, and shows equivalent viral suppression to first-line treatments[29] - The company is expanding Aibond®'s indications to include treated patients based on 96-week clinical data and has submitted a modification application to CDE[30] - The company is developing a three-in-one fixed-dose combination drug, ACC008, which has completed bioequivalence trials and is under registration review by the National Medical Products Administration[31] - The company is focusing on integrating human protein raw material formulations in the anti-inflammatory and stroke fields[33] Financial Management and Governance - The company has not disclosed any profit distribution or capital reserve transfer plans for the reporting period[8] - There are no significant governance issues or non-operational fund occupation by controlling shareholders reported[10] - The report indicates that the financial statements have been declared accurate and complete by the company's responsible personnel[7] - The company has established a management system for the use of raised funds, ensuring compliance with regulations and effective utilization[120] - The company will strictly implement related party transaction procedures to protect its interests and ensure fair pricing[116] Environmental and Social Responsibility - The company successfully passed four environmental protection inspections during the reporting period and identified 87 environmental risks, which were addressed promptly[104] - The company installed monitoring equipment for COD and ammonia nitrogen to ensure compliance with wastewater discharge standards[104] - The company actively participates in charitable activities, providing educational funding to local underprivileged students during the reporting period[108] - The company has established a safety management system to enhance on-site safety management levels[107] - The company continues to comply with national and local environmental laws and regulations without any pollution incidents[104] Shareholder and Equity Management - The company has committed to not transferring or managing its shares for 36 months post-IPO, ensuring shareholder stability[111] - The company has established a three-year shareholder dividend return plan following its IPO, emphasizing cash dividends to enhance shareholder returns[117] - The company will ensure compliance with legal and regulatory requirements in all stock repurchase and shareholder purchase activities[118] - The company has outlined specific conditions under which the lock-up period may be extended or adjusted[112] - The company has a total of 420 million shares, with 87.66% being restricted shares before the change[146] Investment and Capital Allocation - The company has invested a total of approximately RMB 1.43 billion in key research projects as of the report date, with an expected total investment scale including future R&D expenses[53] - The company has allocated $203,300,000 for the research and development of raw material production, with a current investment of $50,808,648.74, achieving 24.99% of the planned investment[141] - The company has reported a shortfall in the expected progress of several clinical projects, primarily due to a shift in focus towards anti-stroke research[141] - The company has incurred a difference of -$500,276,537.78 in the total amount of raised funds compared to the planned investment[140] - The company has approved the use of up to RMB 600 million of temporarily idle raised funds for cash management, with a usage period not exceeding 12 months[142]

Financial Performance - The company's operating revenue for the first half of 2021 was ¥157,003,754.96, representing a 21.97% increase compared to ¥128,719,265.25 in the same period last year[22]. - The net profit attributable to shareholders decreased by 47.49% to ¥12,861,047.88 from ¥24,492,586.55 year-on-year[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 80.96% to ¥3,735,105.70 compared to ¥19,619,358.29 in the previous year[22]. - The net cash flow from operating activities decreased by 214.25%, resulting in a net outflow of ¥46,647,209.22, primarily due to increased cash expenditures for raw material procurement[22]. - The company's gross profit margin for the reporting period was 34.29%, down from 51.86% in the previous year, attributed to a shift in product mix towards lower-margin products[22]. - Basic and diluted earnings per share decreased by 57.14% to ¥0.03 from ¥0.07 year-on-year[23]. - The weighted average return on net assets decreased by 3.37 percentage points to 0.94% compared to 4.31% in the previous year[23]. - The total assets at the end of the reporting period were ¥1,451,886,216.71, a slight increase of 0.35% from ¥1,446,826,965.75 at the end of the previous year[22]. - The net assets attributable to shareholders decreased by 0.59% to ¥1,351,875,755.24 from ¥1,359,856,910.98 at the end of the previous year, mainly due to cash dividend payments[22]. Research and Development - Multiple innovative drugs in the pipeline are at various stages of clinical trials, with potential delays due to regulatory, funding, and talent-related factors impacting R&D progress[6]. - Research and development expenses accounted for 24.2% of operating revenue, an increase of 11.9 percentage points from 12.3% in the previous year[23]. - Total R&D expenses increased significantly to CNY 37,999,316.42, a 140.01% increase compared to the previous period[48]. - The company is actively pursuing research and development in the fields of anti-HIV, anti-inflammatory, and anti-tumor drugs, aligning with international trends[32]. - The company has 16 products in the pipeline, including 8 Class 1 new drugs and 3 Class 2 new drugs, with the first Class 1 innovative drug, Aibond, approved for sale in June 2021[29]. - The company is developing downstream formulations in the human-derived protein sector, including clinical research for new indications of Ustectidine and new formulations of Urekin[4]. - The company has developed a proprietary resin adsorption technology for human-derived proteins, establishing a standardized production process and enhancing supply chain stability[40]. - The company has achieved significant advancements in the synthesis of optical isomers, particularly for ACC006, which demonstrates high purity and stability, suitable for industrial production[43]. Market and Competitive Landscape - The company reported significant reliance on Tianpu Biochemical, which accounted for a high proportion of sales revenue from human-derived proteins, posing a competitive risk in product development[4]. - The company is actively working to reduce its dependency on Tianpu Biochemical as new drugs are developed and launched[4]. - The domestic HIV drug market is expected to exceed 11 billion yuan by 2027, driven by increased patient base, diagnosis rates, and insurance coverage[37]. - The market for Ustikin (乌司他丁) is projected to reach 5 billion yuan by 2027, with significant growth potential in surgical and sepsis applications[39]. - The market for Ureyklin (尤瑞克林) is expected to reach 2.8 billion yuan by 2027, with increased demand following its inclusion in the insurance directory[39]. Drug Development and Approval - The innovative anti-HIV drug Aibond® was successfully approved for market during the reporting period, representing a strategic upgrade over existing non-nucleoside reverse transcriptase inhibitors[5]. - Aibond has shown significant efficacy and safety in clinical trials, with a half-life of approximately 26 hours, allowing for once-daily dosing[29]. - The company is expanding Aibond's indications to include treated HIV-1 patients, with the application accepted by the CDE[30]. - The company is developing a three-in-one fixed-dose combination drug, ACC008, which has completed bioequivalence trials and is under registration review[31]. - The company has initiated clinical trials for AD105, a new indication for an anti-inflammatory drug, with the first subject enrolled in July 2021[33]. - The company is conducting a Phase II clinical trial for ACC006, an anti-tumor drug, with 42 subjects enrolled[34]. Governance and Compliance - There are no significant governance issues or non-operational fund occupation by controlling shareholders reported[10]. - The report indicates that the financial statements have been confirmed for accuracy and completeness by the responsible executives[7]. - The company has not disclosed any profit distribution or capital reserve transfer plans for the reporting period[8]. - The company has established measures to ensure that related party transactions are conducted fairly and do not harm the interests of the company and its subsidiaries[116]. - The company has committed to ensuring transparency and operability in its dividend distribution decision-making process[117]. Environmental and Social Responsibility - The company successfully passed four environmental protection inspections during the reporting period and identified 87 environmental risks, which were addressed promptly[104]. - The company reported no environmental pollution incidents or administrative penalties related to environmental laws during the reporting period[104]. - The company actively participates in charitable activities, providing educational funding to local underprivileged students during the reporting period[108]. - A total of 30 new employees received safety education training, and 20 external personnel underwent safety education during the reporting period[107]. - The company has established a safety management system to enhance on-site safety management levels[107]. Shareholder and Capital Management - The company has committed to not transferring or entrusting management of its shares for 36 months post-IPO[111]. - The company will not reduce its pre-IPO shares until it achieves profitability within three full fiscal years post-IPO[111]. - The company has established a three-year shareholder dividend return plan following its IPO, emphasizing cash dividends to enhance shareholder returns[117]. - The company will prioritize stock repurchase as the first option for stabilizing stock prices, followed by the controlling shareholder's stock purchase[117]. - The company has outlined specific legal responsibilities for any violations of the share transfer commitments[113]. Investment and Financial Management - The total amount allocated for stock repurchase should not be less than 10% of the net profit attributable to shareholders from the previous fiscal year[118]. - The company has invested a total of approximately RMB 1.43 billion in key research projects as of the report date, with an expected total investment scale including future R&D expenses[53]. - The company has approved the use of raised funds to replace previously invested self-raised funds amounting to $13,523.42 million[141]. - The total amount of raised funds for the year is $777,642,000[140]. - The cumulative amount of invested raised funds is $277,365,462.22, indicating a utilization rate of approximately 35.6%[140].

2021 年第一季度报告 公司代码：688488 公司简称：艾迪药业 江苏艾迪药业股份有限公司 2021 年第一季度报告 1 / 22 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 6 | | 四、 | 附录 11 | 2021 年第一季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 | | 本报告期末 | 上年度末 | 本报告期末比上年度末增 | | --- | --- | --- | --- | | | | | 减(%) | | 总资产 | 1,462,603,786.35 | 1,446,826,965.75 | 1.09 | | 归属于上市公司股 | 1,370,932,138.55 | 1,359,856,910.98 | 0.81 | | 东的净资产 | | | | | | 年初至报告期末 | 上年初至上年报告期末 | 比上年同期增减(%) | | 经营活动产生的现 | 2,579,691.55 | 14,629,056.04 | -82.37 | | 金流量净额 | | | | | | 年初至报告期末 | ...

Revenue and Financial Performance - 87.34% of the company's human-derived protein business revenue comes from its largest customer, Tianpu Biochemical[4] - The company plans to distribute cash dividends of RMB 0.48 per 10 shares, totaling approximately RMB 20,160,000[7] - The company's operating revenue for 2020 was CNY 289,056,180.56, a decrease of 16.27% compared to 2019[24] - The net profit attributable to shareholders for 2020 was CNY 39,771,789.32, an increase of 18.20% year-over-year[24] - The net profit after deducting non-recurring gains and losses increased by 26.26% to CNY 26,025,146.91 in 2020[24] - The company's total assets at the end of 2020 were CNY 1,446,826,965.75, an increase of 85.26% from the previous year[24] - The basic earnings per share for 2020 was CNY 0.10, reflecting an 11.11% increase compared to 2019[25] - The net cash flow from operating activities for 2020 was CNY 56,168,654.50, a slight decrease of 0.05% compared to the previous year[24] - The company reported a total non-operating income of 13,746,642.41 RMB for the year 2020, an increase from 12,479,468.74 RMB in 2019, reflecting a growth of approximately 10.2%[31] - The company’s total revenue for the reporting period was CNY 289.06 million, a decrease of 16.27% compared to the previous year[105] - Operating profit increased by 40.77% to CNY 49.55 million, while total profit rose by 23.69% to CNY 47.19 million[105] - The sales of the product Yurekulin increased by 278.91%, significantly contributing to the company's profitability despite a 16.27% decline in overall revenue[109] - The sales of Ustikin decreased by approximately 54.44%, impacting the overall revenue negatively[109] - The gross profit margin for Ustikin was 32.34%, down 11.79% from the previous year due to rising product costs[112] Research and Development - The company has ongoing research for innovative drugs in oncology, with ACC006, ACC010, and ACC015 in early clinical or preclinical stages, indicating significant R&D risks[5] - The company is actively engaged in clinical trials for new drug applications, including investigational new drugs (IND) and new drug applications (NDA)[15] - The company has 14 products in its research pipeline, including 8 Class 1 new drugs and 2 Class 2 new drugs, indicating a strong focus on innovation and development in the pharmaceutical sector[36] - The company aims to enhance its product portfolio by developing new technologies and products in the biopharmaceutical field[15] - The company has developed a method for synthesizing high-purity, low-cost raw materials for ACC007, ACC010, and ACC015, suitable for industrial production[67] - The company has developed a compound formulation technology for ACC008, which includes ACC007, tenofovir fumarate, and lamivudine[67] - The company has developed a method for preparing and characterizing the crystal form of ACC006, which has high purity and stability[67] - The company has developed a PEG modification technology that enhances the bioavailability and efficacy of drugs[67] - The company has achieved a significant reduction in production costs and improved optical purity for ACC006, making it suitable for industrial production[67] - The company has 52 R&D personnel, accounting for 13.13% of total employees, with an average salary of 20.16 thousand RMB[79] - The company has a total of 36 authorized patents and is involved in three major national drug creation projects[87] - The company aims to develop innovative drugs targeting major diseases such as HIV, inflammation, stroke, and malignant tumors, aligning with national health strategies[85] Product Development and Pipeline - The innovative drug ACC007 for HIV has completed Phase III clinical trials and is under review by the National Medical Products Administration, with uncertain approval status[5] - The company is developing a generic version of Ustectidine and exploring new indications, facing direct competition from Tianpu Biochemical[4] - The company has initiated a Phase I clinical trial for the new indication of AD105 (Ustekinumab), demonstrating its commitment to expanding its product offerings[38] - The company is advancing its clinical research in the oncology field, with ongoing Phase II and Phase I trials for new drugs ACC006 and ACC010, respectively[39] - The company is currently conducting clinical research for ACC017, an integrase inhibitor for HIV, with an investment of ¥218,803.27 and a total expected investment of ¥18,000,000[75] - The company aims to simplify treatment regimens and improve patient outcomes in HIV treatment through its innovative drug development strategies[36] - The company is focusing on developing new products such as coagulation-regulating proteins and epidermal growth factors based on its human-derived protein platform[64] - The company is committed to enhancing its research and development capabilities in oncology drugs, establishing a robust chemical drug technology system[168] - The company is focusing on three major disease areas: HIV treatment, human-derived proteins, and cancer therapy, with plans to develop a series of proprietary combination products for HIV treatment[172] Market Strategy and Expansion - The company is focused on expanding its market presence through strategic partnerships and potential acquisitions in the pharmaceutical sector[15] - The company has established a marketing network covering 12 provinces, with over 70% of national patients in these areas, facilitating future sales of its products[89] - The company is exploring overseas markets, particularly in India and through a joint venture with Kainos in South Korea, to enhance competitiveness and sales of human-derived protein products[174] - The company plans to enhance transparency and operational feasibility in its dividend distribution policy, establishing a three-year shareholder dividend return plan post-IPO[193] - The company is committed to ensuring that every HIV patient can choose the most suitable treatment based on their condition, marking a new era in personalized HIV treatment[172] Risks and Challenges - The company emphasizes the potential risks associated with its future plans and development strategies, advising investors to be cautious[9] - The company faces risks related to core competitiveness, including potential breakthroughs by competitors in resin adsorption technology, which could impact its market position[100] - The company’s human-derived protein business heavily relies on Tianpu Biochemical, which accounted for 87.34% of its revenue, posing a risk if the client’s business fluctuates[101] - The company is exposed to risks from rising raw material prices, despite having stable supplier relationships[102] - The company faces risks related to raw material shortages and pricing pressures, which could adversely affect production and operations[103] Corporate Governance and Compliance - The company has established a comprehensive internal control system and management framework to improve operational efficiency and reduce operational costs[196] - The company will strictly implement voting procedures and avoidance systems for related party transactions to protect its interests[193] - The company has committed to improving corporate governance to ensure the protection of shareholders' rights and interests[197] - The company will ensure compliance with laws and regulations in its operations and governance practices[197] - The company will disclose the controlling shareholder's stock increase plan within ten trading days after the conditions for increasing shares are met[194] Financial Management and Investment - The company has made significant equity investments totaling approximately 296.24 million RMB, a year-on-year increase of 1,121.33%[159] - The company increased its investment in its wholly-owned subsidiary by 68 million RMB and in another subsidiary by 204.3 million RMB during the reporting period[160] - The company plans to invest the raised funds in innovative drug research and the purchase of a research and development center building, as well as in raw material drug production and supporting facilities[196] - The company will strengthen the management of raised funds to ensure their proper and efficient use, with a focus on compliance with regulations[196]

2020 年第三季度报告 公司代码：688488 公司简称：艾迪药业 江苏艾迪药业股份有限公司 2020 年第三季度报告 1 / 28 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 7 | | 四、 | 附录 | 10 | 2020 年第三季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上年度末增 减(%) 总资产 1,404,320,266.34 780,980,835.28 79.81 归属于上市公司 股东的净资产 1,349,606,959.34 556,236,958.54 142.63 年初至报告期末 （1-9 月） 上年初至上年报告期末 （1-9 月） 比上年同期增减(%) 经营活动产生的 现金流量净额 64,993,643.07 80,612,679.33 -19.38 年初至报告期末 （1-9 月） 上年初至上年报告期末 （1-9 月） 比上年同期增减 （%） 营业收入 189,911,94 ...